Anti-PKM antibody [EPR10138(B)]

4 product images

• 

  Western blot - Anti-PKM antibody [EPR10138(B)] (ab150377)

  All lanes: Western blot - Anti-PKM antibody [EPR10138(B)] (ab150377) at 1/10000 dilution

  Lane 1: HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysate

  Lane 2: Jurkat (Human T cell leukemia T lymphocyte) whole cell lysate

  Lane 3: A549 (Human lung carcinoma epithelial cell) whole cell lysate

  Lane 4: Mouse lung lysate

  Lane 5: Human skeletal muscle lysate

  Lane 6: Rat skeletal muscle lysate

  Lane 7: Mouse skeletal muscle lysate

  Secondary

  All lanes: Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution

  Predicted band size: 58 kDa

  Observed band size: 58 kDa

• 

  Flow Cytometry (Intracellular) - Anti-PKM antibody [EPR10138(B)] (ab150377)

  Flow Cytometry analysis of HeLa (Human cervix adenocarcinoma epithelial cell) cells labelling PKM with Purified ab150377 at 1:50 dilution (10 μg/ml) (Red). Cells were fixed with 4% Paraformaldehyde and permeabilised with 90% Methanol. A Goat anti rabbit IgG (Alexa Fluor™ 488, Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077) secondary antibody was used at 1:2000. Isotype control - Rabbit monoclonal IgG (Black). Unlabelled control - Cell without incubation with primary antibody and secondary antibody (Blue).

• 

  Immunocytochemistry/ Immunofluorescence - Anti-PKM antibody [EPR10138(B)] (ab150377)

  Immunocytochemistry analysis of A549(Human lung carcinoma epithelial cell) cells labeling PKM with Purified ab150377 at 1/50 dilution (10 µg/mL). Cells were fixed in 4% Paraformaldehyde and permeabilized with 0.1% tritonX-100. Cells were counterstained with Alexa Fluor® 594 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker ab195889 Anti-alpha Tubulin antibody [DM1A+H10:L10] - Microtubule Marker (Alexa Fluor® 594) 1/200 (2.5 µg/mL). Goat anti rabbit IgG (Alexa Fluor® 488, Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077) was used as the secondary antibody at 1/1000 (2 µg/mL) dilution. DAPI (blue) was used as nuclear counterstain. PBS instead of the primary antibody was used as the secondary antibody only control.

• 

  Image collected and cropped by CiteAb under a CC-BY license from the publication

  Western blot - Anti-PKM antibody [EPR10138(B)] (ab150377)

  PKM western blot using anti-PKM antibody [EPR10138(B)] ab150377. Publication image and figure legend from Yu, G., Yu, W., et al., 2015, Mol Cancer, PubMed 26576639.

  
  

  ab150377 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab150377 please see the product overview.

  HK1, PKM2, and PFKB expression and its association with survival durations in patients with HC. a, HK1, PKM2, and PFKB expression in normal bile duct tissue (left panels), tumors (middle panels), and quantitative representations staining (right panels). Original magnification, ×400. b, patients with high HK1 expression had a shorter median time to recurrence than did those with low HK1 expression (12 months versus 39 months). Cum, cumulative. c, patients with high PKM2-expressing tumors had a significantly shorter median time to recurrence than did patients with low PKM2-expressing tumors (11 months versus 32 months). d, the median OS duration was significantly worse in patients with high expression of HK1 (15 months) than in those with low expression of HK1 (46 months). e, the median OS duration was significantly worse in patients with high expression of PKM2 (14 months) than in those with low expression of PKM2 (40 months)